Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 16/20 | 0.53 |
| ▸ | TMPRSS15 | P98073 | 16/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7311814 | 0.91 | TMPRSS15 (0.54) | PRSS1TMPRSS15 | |
| SCHEMBL7311831 | 0.91 | TMPRSS15 (0.54) | PRSS1TMPRSS15 | |
| Butane SCHEMBL3237834 | 0.86 | PRSS1 (0.54) | PRSS1TMPRSS15 | |
| Butane SCHEMBL3238792 | 0.84 | PRSS1 (0.56) | PRSS1TMPRSS15 | |
| Butane SCHEMBL3238160 | 0.84 | PRSS1 (0.56) | PRSS1TMPRSS15 | |
| Butane SCHEMBL3231173 | 0.81 | TMPRSS15 (0.59) | PRSS1TMPRSS15ITGB3ITGA2B | |
| SCHEMBL7186153 | 0.78 | PRSS1 (0.44) | PRSS1TMPRSS15TAS1R3TAS1R1 | |
| SCHEMBL7186155 | 0.78 | PRSS1 (0.44) | PRSS1TMPRSS15TAS1R3TAS1R1 | |
| Butane SCHEMBL3243913 | 0.77 | PRSS1 (0.54) | PRSS1TMPRSS15 | |
| SCHEMBL7312959 | 0.77 | TMPRSS15 (0.56) | PRSS1TMPRSS15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671057-B2 | Therapeutic agent for type II diabetes comprising protease-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20080009537-A1 | Therapeutic Agent for Diabetes Comprising Protease-Inhibiting Compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-1815865-A1 | THERAPEUTIC AGENT FOR DIABETES COMPRISING PROTEASE-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009537-A1 | Therapeutic Agent for Diabetes Comprising Protease-Inhibiting Compound | DPP4, IAPP, DPP7 | PRSS1 25/4885TMPRSS15 21/4885TAS1R3 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.